Johnson & JohnsonvsKrystal Biotech

JNJ and KRYS stock compared: price, dividend, valuation and results, from SEC filings.

KRYS

Krystal Biotech, Inc.

$315.34

Value $9.2B

+5.62%
KRYS's page

Johnson & Johnson (JNJ) has a market value of $657B and Krystal Biotech (KRYS) $9.2B. Over the last year, with dividends, JNJ moved +39.7% and KRYS +51.4%. The P/E is 40.8 for JNJ and 40.9 for KRYS. Dividend yield: JNJ 1.94%, KRYS none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$657B

    KRYS$9.2B

    JNJ is 71 times KRYS

  • Revenue, 12 months

    JNJ$99.3B

    KRYS$470M

    JNJ is 211 times KRYS

  • Net income, 12 months

    JNJ$16.1B

    KRYS$225M

    JNJ is 71 times KRYS

  • Operating margin

    JNJ–

    KRYS48.4%

  • ROIC

    JNJ12.4%

    KRYS15.4%

    3.0 points apart

  • P/E

    JNJ40.8

    KRYS40.9

    About the same

  • Dividend yield

    JNJ1.9%

    KRYS0.0%

    1.9 points apart

  • 5-year return

    JNJ+92.0%

    KRYS+542.4%

    450.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+92.0%

KRYS+542.4%

20040060020222023202420252026
Returns by period
PeriodJNJWith dividendsKRYSWith dividends
1 year since November 17, 2025+39.7%Price +36.6%+51.4%Price +51.4%
3 years since November 17, 2023+98.2%+25.6% a yearPrice +82.1%+202.7%+44.7% a yearPrice +202.7%
5 years since November 17, 2021+92.0%+13.9% a yearPrice +67.0%+542.4%+45.1% a yearPrice +542.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonKRYSKrystal Biotech

Valuation

JNJKRYS
Valuation
Price$272.70$315.34
Market value$657B$9.2B
Enterprise value (EV)$685B$8.3B
P/E40.840.9
P/E, 5-year median21.9–
P/B8.16.4
EV/EBIT38.636.5
Free cash flow yield3.1%3.4%

Results and growth

JNJKRYS
Results and growth
Revenue, 12 months$99.3B$470M
Net income, 12 months$16.1B$225M
Free cash flow, 12 months$20.6B$310M
Earnings per share, 12 months$6.59$7.37
Revenue growth, year on year6.1%33.9%
Revenue growth a year, past+2.7%over 5 years–
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJKRYS
Margins and returns on capital
Gross margin67.6%–
Operating margin–48.4%
Net margin16.2%47.9%
ROIC12.4%15.4%
ROE19.7%17.5%

Balance sheet

JNJKRYS
Balance sheet
Cash$17.2B$912M
Total debt$44.7B$8.6M
Net debt / EBITDA1.1-3.9
Interest cover18.0×–

Dividends and buybacks

JNJKRYS
Dividends and buybacks
Dividend yield1.9%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or KRYS

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Krystal Biotech?

By market value, Johnson & Johnson ($657B) is about 71.3 times Krystal Biotech ($9.2B), at today's prices.

How did JNJ and KRYS stock do over the last 5 years?

Since November 17, 2021, JNJ's price moved +67.0% and KRYS's +542.4%. With dividends: JNJ +92.0% (+13.9% a year), KRYS +542.4% (+45.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or KRYS?

The dividend yield at today's price is 1.94% for Johnson & Johnson and none for Krystal Biotech. Over the last twelve months they paid $5.28 and – per share.

What is the P/E of JNJ and KRYS?

At today's price, the P/E is 40.8 for JNJ and 40.9 for KRYS. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Johnson & Johnson or Krystal Biotech?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 47.9% for Krystal Biotech, and the operating margin – and 48.4%. Revenue was $99.3B and $470M.

Which is the better investment, Johnson & Johnson or Krystal Biotech?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.